EUVIMEDEUVIMED entdecken
Crossref

Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 + T-myeloid cell networks in melanoma

David Barras iD, Eleonora Ghisoni iD, Johanna Chiffelle iD, Angela Orcurto, Julien Dagher iD, Noémie Fahr iD, Fabrizio Benedetti iD, Isaac Crespo, Alizée J Grimm, Matteo Morotti iD, Stefan Zimmermann, Rafael Duran iD und 33 weitere

Science Immunology · 02.02.2024 · 9 (92)

DOI: 10.1126/sciimmunol.adg7995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, erschienen am 02.02.2024. Verfasst von David Barras und 44 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV),…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Melanoma. Die Arbeit wurde bisher 111-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive cell therapy (ACT) using ex vivo–expanded tumor-infiltrating lymphocytes (TILs) can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a fraction of patients. Using longitudinal samples from 13 patients with metastatic melanoma treated with TIL-ACT in a phase 1 clinical study, we interrogated cellular states within the tumor microenvironment (TME) and their interactions. We performed bulk and single-cell RNA sequencing, whole-exome sequencing, and spatial proteomic analyses in pre- and post-ACT tumor tissues, finding that ACT responders exhibited higher basal tumor cell–intrinsic immunogenicity and mutational burden. Compared with nonresponders, CD8 + TILs exhibited increased cytotoxicity, exhaustion, and costimulation, whereas myeloid cells had increased type I interferon signaling in responders. Cell-cell interaction prediction analyses corroborated by spatial neighborhood analyses revealed that responders had rich baseline intratumoral and stromal tumor–reactive T cell networks with activated myeloid populations. Successful TIL-ACT therapy further reprogrammed the myeloid compartment and increased TIL-myeloid networks. Our systematic target discovery study identifies potential T-myeloid cell network–based biomarkers that could improve patient selection and guide the design of ACT clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveMelanomaHumansLymphocytes, Tumor-InfiltratingProteomicsCD8-Positive T-LymphocytesTumor Microenvironment

Autor:innen und Institutionen

  • Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.
  • Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.
  • Service of Immuno-oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
  • Unit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
  • Department of Radiology and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.
  • Flow Cytometry Facility, Department of Formation and Research, University of Lausanne, Epalinges, Switzerland.

ORCID-Profile: David Barras, Eleonora Ghisoni, Johanna Chiffelle, Julien Dagher, Noémie Fahr, Fabrizio Benedetti, Matteo Morotti, Rafael Duran, Martina Imbimbo, Maria Ochoa de Olza, Krisztian Homicsko, Sara Bobisse, Rémy Pétremand, Reinhard Dummer, Gregoire Berthod, Jonathan Thevenet, Michal Bassani-Sternberg, John O Prior, Maurice Matter, Veronica Aedo, Clarisse Dromain, Jesus Corria-Osorio, Stéphanie Tissot, Lana E Kandalaft, Raphael Gottardo, Mikaël Pittet, Christine Sempoux, Urania Dafni, Alexandre Harari, Denarda Dangaj Laniti, George Coukos

Zitieren

APA

Barras, D., Ghisoni, E., Chiffelle, J., Orcurto, A., Dagher, J., Fahr, N., Benedetti, F., Crespo, I., Grimm, A. J., Morotti, M., Zimmermann, S., Duran, R., Imbimbo, M., de Olza, M. O., Navarro, B., Homicsko, K., Bobisse, S., Labes, D., Tsourti, Z., …, & Coukos, G. (2024). Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 + T-myeloid cell networks in melanoma. Science Immunology, 9(92). https://doi.org/10.1126/sciimmunol.adg7995

Vancouver

Barras D, Ghisoni E, Chiffelle J, Orcurto A, Dagher J, Fahr N, et al. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 + T-myeloid cell networks in melanoma. Science Immunology. 2024;9(92). doi:10.1126/sciimmunol.adg7995

BibTeX
@article{Barras2024,
  author = {Barras, David and Ghisoni, Eleonora and Chiffelle, Johanna and Orcurto, Angela and Dagher, Julien and Fahr, Noémie and Benedetti, Fabrizio and Crespo, Isaac and Grimm, Alizée J and Morotti, Matteo and Zimmermann, Stefan and Duran, Rafael and Imbimbo, Martina and de Olza, Maria Ochoa and Navarro, Blanca and Homicsko, Krisztian and Bobisse, Sara and Labes, Danny and Tsourti, Zoe and Andriakopoulou, Charitini and Herrera, Fernanda and Pétremand, Rémy and Dummer, Reinhard and Berthod, Gregoire and Kraemer, Anne I and Huber, Florian and Thevenet, Jonathan and Bassani-Sternberg, Michal and Schaefer, Niklaus and Prior, John O and Matter, Maurice and Aedo, Veronica and Dromain, Clarisse and Corria-Osorio, Jesus and Tissot, Stéphanie and Kandalaft, Lana E and Gottardo, Raphael and Pittet, Mikaël and Sempoux, Christine and Michielin, Olivier and Dafni, Urania and Trueb, Lionel and Harari, Alexandre and Laniti, Denarda Dangaj and Coukos, George},
  title = {Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 + T-myeloid cell networks in melanoma},
  journal = {Science Immunology},
  year = {2024},
  volume = {9},
  number = {92},
  doi = {10.1126/sciimmunol.adg7995}
}
Kostenlos starten →